Clinical trials: Ischemic Stroke, completed
Stroke, Myocardial Infarction
Insulin Resistance Intervention After Stroke Trial
The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
- Conditions
- Stroke, Myocardial Infarction, Diabetes
- Trial name
- IRIS (NCT00091949)
- Testing
- pioglitazone
- Where
- 183 sites in United States, Australia and 6 more
- Volunteers
- 3,876 people
- Sponsor
- Yale University
Ischemic Stroke
Safety of Intravenous Thrombolysis for Wake-up Stroke
The purpose is to demonstrate the safety of intravenous tissue plasminogen activator (IV t-PA) in ischemic stroke patients who present to the emergency department (ED) after awakening with the symptoms of suspected ischemic…
- Trial name
- Wake-Up Stroke (NCT01183533)
- Testing
- Alteplase (iv t-PA)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Ischemic Stroke
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment.
- Trial name
- EAISE (NCT04309474)
- Testing
- Elezanumab
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 121 people
- Sponsor
- AbbVie
Ischemic Stroke
Community Engagement for Early Recognition and Immediate Action in Stroke
The investigators plan to develop and adapt a community-partnered intervention using community health promoters ("Stroke Promoters") to deliver messaging regarding stroke symptom awareness and the need for calling 911 after…
- Trial name
- CEERIAS (NCT02301299)
- Testing
- Community-based Stroke Awareness Program
- Where
- United States
- Volunteers
- 1,322 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Cerebral Infarction
Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
RATIONALE: Elevation in pulsatility indices (PIs), measured by transcranial Doppler (TCD), has been postulated to reflect downstream increased vascular resistance caused by small-vessel disease (SVD).
- Trial name
- ECLIPse (NCT00741286)
- Testing
- Aspirin, cilostazol
- Where
- 8 sites in South Korea
- Volunteers
- 203 people
- Sponsor
- Inje University
Ischemic Stroke
Mayo Acute Stroke Trial for Enhancing Recovery
This study involves treating patients that have suffered an acute ischemic stroke with the medication donepezil (Aricept ®). The hypothesis is that taking donepezil (FDA-approved for the treatment of Alzheimer's Disease) for the…
- Trial name
- MASTER (NCT00805792)
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Cardiovascular Disease, Peripheral Arterial Disease
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK-0524A) versus matching placebo on the risk of heart attack or coronary death…
- Conditions
- Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus, Coronary Heart Disease
- Trial name
- HPS2-THRIVE (NCT00461630)
- Testing
- ER niacin/laropiprant, simvastatin, ezetimibe/simvastatin
- Where
- United Kingdom
- Volunteers
- 25,673 people
- Sponsor
- University of Oxford
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30…
- Trial name
- ORIGINAL (NCT04915729)
- Testing
- tenecteplase, alteplase
- Where
- 55 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Aortic Stenosis, Brain Infarction
Neuroprotection in Patients Undergoing Aortic Valve Replacement
To evaluate the efficacy and safety of embolic protection devices to reduce ischemic brain injury in patients undergoing surgical aortic valve replacement (AVR).
- Conditions
- Aortic Stenosis, Brain Infarction, Cerebrovascular Accident, Stroke
- Trial name
- NCT02389894
- Testing
- Embol-X Embolic Protection Device, CardioGard Cannula
- Where
- 18 sites in United States, Canada
- Volunteers
- 383 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ischemic Stroke
TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion
This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours.
- Trial name
- TEMPO-1 (NCT01654445)
- Testing
- Tenecteplase
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Calgary
Diabetes Mellitus, Hypertension
Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up
The purpose of this study is to identify risk factors for insulin resistance and to investigate the influence of insulin sensitivity on development of cardiovascular risk markers like blood pressure, heart rate, body build…
- Conditions
- Diabetes Mellitus, Hypertension, Ischemic Heart Disease, Stroke
- Trial name
- INFO (NCT01412554)
- Where
- Norway
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Cardiovascular Disease
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
SEARCH is a randomised, double-blind, multi-centre United Kingdom (UK) trial of 12,064 patients with myocardial infarction (MI) prior to study entry which aims to demonstrate whether a more intensive cholesterol lowering regimen…
- Trial name
- SEARCH (NCT00124072)
- Testing
- Simvastatin 20 mg daily, Folic acid 2 mg + vitamin B12 1 mg daily, Simvastatin 80 mg daily
- Where
- United Kingdom
- Volunteers
- 12,064 people
- Sponsor
- University of Oxford
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke, Biofeedback
Effects of Biofeedback in Patients With Acute Cerebral Infarction
The major aim of this study is to investigate the effects of biofeedback assisted abdominal breathing training on improving the psychological and physiological distress in patients with ACI.
- Conditions
- Acute Ischemic Stroke, Biofeedback, Autonomic Dysfunction, Cognitive Function, Psychological Distress
- Trial name
- NCT03516227
- Testing
- heart rate variability biofeedback
- Volunteers
- 40 people
- Sponsor
- National Defense Medical Center, Taiwan
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Cerebral Infarction
Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
This study will recruit 316 ischemic stroke patients taking aspirin. They will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month.
- Trial name
- ARCC (NCT00446641)
- Testing
- Cilostazol
- Where
- 4 sites in South Korea
- Volunteers
- 244 people
- Sponsor
- Asan Medical Center
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin.
- Trial name
- NCT01014975
- Testing
- Plasmin (Human)
- Where
- 23 sites in Australia, Austria and 4 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim